485 related articles for article (PubMed ID: 22528766)
1. HIV and inflammation: mechanisms and consequences.
Hunt PW
Curr HIV/AIDS Rep; 2012 Jun; 9(2):139-47. PubMed ID: 22528766
[TBL] [Abstract][Full Text] [Related]
2. Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection.
Hunt PW; Lee SA; Siedner MJ
J Infect Dis; 2016 Oct; 214 Suppl 2(Suppl 2):S44-50. PubMed ID: 27625430
[TBL] [Abstract][Full Text] [Related]
3. Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.
Hsu DC; Sereti I
Drugs; 2016 Apr; 76(5):533-49. PubMed ID: 26915027
[TBL] [Abstract][Full Text] [Related]
4. Circulating LPS and (1→3)-β-D-Glucan: A Folie à Deux Contributing to HIV-Associated Immune Activation.
Ramendra R; Isnard S; Mehraj V; Chen J; Zhang Y; Finkelman M; Routy JP
Front Immunol; 2019; 10():465. PubMed ID: 30967860
[TBL] [Abstract][Full Text] [Related]
5. Th17, gut, and HIV: therapeutic implications.
Hunt PW
Curr Opin HIV AIDS; 2010 Mar; 5(2):189-93. PubMed ID: 20543599
[TBL] [Abstract][Full Text] [Related]
6. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART.
Zicari S; Sessa L; Cotugno N; Ruggiero A; Morrocchi E; Concato C; Rocca S; Zangari P; Manno EC; Palma P
Viruses; 2019 Feb; 11(3):. PubMed ID: 30818749
[TBL] [Abstract][Full Text] [Related]
7. Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection.
Freeman ML; Lederman MM; Gianella S
Curr HIV/AIDS Rep; 2016 Feb; 13(1):10-9. PubMed ID: 26810437
[TBL] [Abstract][Full Text] [Related]
8. Residual immune dysregulation syndrome in treated HIV infection.
Lederman MM; Funderburg NT; Sekaly RP; Klatt NR; Hunt PW
Adv Immunol; 2013; 119():51-83. PubMed ID: 23886064
[TBL] [Abstract][Full Text] [Related]
9. Examining Relationships between Metabolism and Persistent Inflammation in HIV Patients on Antiretroviral Therapy.
Ahmed D; Roy D; Cassol E
Mediators Inflamm; 2018; 2018():6238978. PubMed ID: 30363715
[TBL] [Abstract][Full Text] [Related]
10. Managing HIV-associated inflammation and ageing in the era of modern ART.
Bloch M; John M; Smith D; Rasmussen TA; Wright E
HIV Med; 2020 Oct; 21 Suppl 3():2-16. PubMed ID: 33022087
[TBL] [Abstract][Full Text] [Related]
11. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy.
Deeks SG
Top HIV Med; 2009; 17(4):118-23. PubMed ID: 19890183
[TBL] [Abstract][Full Text] [Related]
12. Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV.
Fitzgerald FC; Lhomme E; Harris K; Kenny J; Doyle R; Kityo C; Shaw LP; Abongomera G; Musiime V; Cook A; Brown JR; Brooks A; Owen-Powell E; Gibb DM; Prendergast AJ; Sarah Walker A; Thiebaut R; Klein N;
J Infect Dis; 2019 Jan; 219(1):89-100. PubMed ID: 30107546
[TBL] [Abstract][Full Text] [Related]
13. HIV infection and atherosclerosis: evaluating the drivers of inflammation.
Maniar A; Ellis C; Asmuth D; Pollard R; Rutledge J
Eur J Prev Cardiol; 2013 Oct; 20(5):720-8. PubMed ID: 22556374
[TBL] [Abstract][Full Text] [Related]
14. Impact of HIV infection on aging and immune status.
Blanco JR; Negredo E; Bernal E; Blanco J
Expert Rev Anti Infect Ther; 2021 Jun; 19(6):719-731. PubMed ID: 33167724
[No Abstract] [Full Text] [Related]
15. Cannabinoids and inflammation: implications for people living with HIV.
Costiniuk CT; Jenabian MA
AIDS; 2019 Dec; 33(15):2273-2288. PubMed ID: 31764093
[TBL] [Abstract][Full Text] [Related]
16. Plasma Biomarkers of Human Immunodeficiency Virus-Related Systemic Inflammation and Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral Therapy.
Kroeze S; Wit FW; Rossouw TM; Steel HC; Kityo CM; Siwale M; Akanmu S; Mandaliya K; de Jager M; Ondoa P; Reiss P; Rinke de Wit TF; Kootstra N; Hamers RL
J Infect Dis; 2019 Aug; 220(6):1029-1033. PubMed ID: 31086991
[TBL] [Abstract][Full Text] [Related]
17. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.
Hunt PW; Cao HL; Muzoora C; Ssewanyana I; Bennett J; Emenyonu N; Kembabazi A; Neilands TB; Bangsberg DR; Deeks SG; Martin JN
AIDS; 2011 Nov; 25(17):2123-31. PubMed ID: 21881481
[TBL] [Abstract][Full Text] [Related]
18. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.
Wallet MA; Rodriguez CA; Yin L; Saporta S; Chinratanapisit S; Hou W; Sleasman JW; Goodenow MM
AIDS; 2010 Jun; 24(9):1281-90. PubMed ID: 20559035
[TBL] [Abstract][Full Text] [Related]
19. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.
Gandhi RT; McMahon DK; Bosch RJ; Lalama CM; Cyktor JC; Macatangay BJ; Rinaldo CR; Riddler SA; Hogg E; Godfrey C; Collier AC; Eron JJ; Mellors JW;
PLoS Pathog; 2017 Apr; 13(4):e1006285. PubMed ID: 28426825
[TBL] [Abstract][Full Text] [Related]
20. Immune activation and HIV persistence: considerations for novel therapeutic interventions.
Hatano H
Curr Opin HIV AIDS; 2013 May; 8(3):211-6. PubMed ID: 23454864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
